No Data
No Data
Enanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy Buchanan
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $20
Oppenheimer Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating, Maintains Target Price $14
Enanta Pharmaceuticals (ENTA) Gets a Hold From Oppenheimer
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $21
Enanta Pharmaceuticals' RSV Platform Advances: Buy Rating Affirmed on Promising Clinical Data